Brokerages expect Zoetis Inc (NYSE:ZTS) to announce $0.77 earnings per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Zoetis’ earnings, with estimates ranging from $0.75 to $0.79. Zoetis posted earnings of $0.69 per share in the same quarter last year, which would suggest a positive year over year growth rate of 11.6%. The firm is scheduled to announce its next earnings results on Thursday, February 21st.

According to Zacks, analysts expect that Zoetis will report full year earnings of $3.11 per share for the current year, with EPS estimates ranging from $3.08 to $3.13. For the next fiscal year, analysts anticipate that the business will post earnings of $3.46 per share, with EPS estimates ranging from $3.29 to $3.57. Zacks’ EPS averages are a mean average based on a survey of research firms that that provide coverage for Zoetis.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, November 1st. The company reported $0.83 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.77 by $0.06. Zoetis had a net margin of 20.35% and a return on equity of 75.51%. The firm had revenue of $1.48 billion for the quarter, compared to the consensus estimate of $1.46 billion. During the same period in the prior year, the firm posted $0.65 earnings per share. The firm’s quarterly revenue was up 9.9% compared to the same quarter last year.

ZTS has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. increased their price target on shares of Zoetis from $100.00 to $101.00 and gave the stock an “overweight” rating in a report on Friday, November 2nd. Morgan Stanley set a $100.00 price objective on shares of Zoetis and gave the stock a “hold” rating in a research report on Friday, November 2nd. Cantor Fitzgerald restated an “overweight” rating and set a $105.00 price objective (up from $98.00) on shares of Zoetis in a research report on Wednesday, October 17th. Zacks Investment Research cut shares of Zoetis from a “buy” rating to a “hold” rating in a research report on Friday, October 5th. Finally, BMO Capital Markets restated a “hold” rating on shares of Zoetis in a research report on Sunday, November 11th. Six equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $94.00.

In other news, insider Roxanne Lagano sold 2,000 shares of the stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $92.03, for a total value of $184,060.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Willie M. Reed sold 3,205 shares of the stock in a transaction dated Friday, November 30th. The shares were sold at an average price of $93.74, for a total transaction of $300,436.70. Following the completion of the sale, the director now owns 566 shares of the company’s stock, valued at $53,056.84. The disclosure for this sale can be found here. Insiders sold 167,011 shares of company stock valued at $15,847,524 over the last quarter. Company insiders own 0.35% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of ZTS. Sun Life Financial INC raised its position in shares of Zoetis by 604.3% in the second quarter. Sun Life Financial INC now owns 1,310 shares of the company’s stock valued at $112,000 after buying an additional 1,124 shares during the last quarter. Signature Estate & Investment Advisors LLC acquired a new stake in Zoetis during the third quarter worth about $112,000. Capital Bank & Trust Co increased its position in Zoetis by 206.5% during the third quarter. Capital Bank & Trust Co now owns 1,269 shares of the company’s stock worth $116,000 after purchasing an additional 855 shares during the last quarter. Capital Guardian Trust Co. acquired a new stake in Zoetis during the third quarter worth about $117,000. Finally, Migdal Insurance & Financial Holdings Ltd. increased its position in Zoetis by 3,033.3% during the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,410 shares of the company’s stock worth $120,000 after purchasing an additional 1,365 shares during the last quarter. Institutional investors and hedge funds own 89.94% of the company’s stock.

Shares of NYSE ZTS opened at $90.57 on Monday. Zoetis has a 1 year low of $70.20 and a 1 year high of $96.57. The firm has a market cap of $43.51 billion, a P/E ratio of 37.74, a PEG ratio of 1.79 and a beta of 0.99. The company has a current ratio of 4.06, a quick ratio of 2.63 and a debt-to-equity ratio of 3.04.

The firm also recently announced a quarterly dividend, which was paid on Monday, December 3rd. Stockholders of record on Tuesday, November 20th were given a $0.126 dividend. This represents a $0.50 dividend on an annualized basis and a dividend yield of 0.56%. The ex-dividend date was Monday, November 19th. Zoetis’s dividend payout ratio (DPR) is 20.83%.

About Zoetis

Zoetis, Inc discovers, develops and manufactures a portfolio of animal health medicines and vaccines. Its products are complemented by diagnostic products, genetic tests, bio devices and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal. The firm provides its services though five categories namely, anti-invectives, vaccines, parasitic ides, medicated feed additives, and other pharmaceuticals.

Read More: How to Invest in an Index Fund

Get a free copy of the Zacks research report on Zoetis (ZTS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.